Full Title A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients with Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric) Purpose The purpose of this study […]
brittnay
April 24, 2023 – The combined signatures of the tumour microenvironment and nucleotide metabolism-related genes provide a prognostic and therapeutic biomarker for gastric cancer
Abstract: The tumour microenvironment (TME) is vital to tumour development and influences the immunotherapy response. Abnormal nucleotide metabolism (NM) not only promotes tumour cell proliferation but also inhibits immune responses […]
April 21, 2023 – No Survival Benefit With NAC for Advanced Stomach Cancer
Abstract: Background Despite the lack of decisive research advocating neoadjuvant chemotherapy, there is a broad consensus that it is beneficial for gastric cancer in terms of survival. However, there is […]
April 21, 2023 – Tislelizumab/Chemo Demonstrates Improved Survival in Gastric/GEJ Cancer
Combination treatment with tislelizumab (BGB-A317) and chemotherapy resulted in superior overall survival (OS) vs chemotherapy in the treatment of patients with advanced unresectable metastatic gastric or gastroesophageal (GEJ) adenocarcinoma regardless […]
April 21, 2023 – Zolbetuximab/mFOLFOX6 Prolongs Survival in Locally Advanced Gastric Cancer
Treatment with zolbetuximab (IMAB362) and modified folinic acid, fluorouracil, and oxaliplatin (mFOLFOX6) may represent a new standard of care in first-line CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or […]
April 20, 2023 – BeiGene, Novartis’ tislelizumab stages comeback with broader stomach cancer trial win
When BeiGene and Novartis announced a partial trial win for tislelizumab in stomach cancer, doubts started to circulate around the PD-1 inhibitor’s potential. Now, the partners have come back with […]
April 17, 2023 – Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, April 17, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, […]
April 17, 2023 – Self-Care Strategies for Coping With Scanxiety During Cancer Treatment
Image by KieferPix on Shutterstock Being diagnosed with stomach cancer can be overwhelming. The thought of undergoing tests and medical scans can add more stress and worry, leading to scanxiety. […]
April 13, 2023 – FDA Accepts sBLA for Pembrolizumab/Chemo in Gastric or GEJ Adenocarcinoma
The FDA has accepted a supplemental biologics license application for pembrolizumab (Keytruda) in combination with chemotherapy as a first-line treatment for patients with locally advanced unresectable or metastatic gastric or […]
April 12, 2023 – Trastuzumab Biosimilar BLA Accepted for HER2+ Breast Cancer and Gastric Cancer
HLX02, a proposed trastuzumab (Herceptin) biosimilar, has had its biologics license application (BLA) accepted by the FDA. The treatment has been proposed as an adjuvant therapy for HER2-overexpressing breast cancer, HER2-overexpressing […]